With new partners at Allogene Therapeutics, Cellectis $CLLS is ready to hustle its off-the-shelf CAR-T therapies to the market — taking advantage of $164 million it’s just raised from a public offering.
The Paris-based biotech spelled out the intended uses of the proceeds in an SEC filing, allocating $100 million to establish commercial capabilities for its current immuno-oncology candidates, $20 million for an additional UCART product candidate, and $30 million to pursue a non-oncology application of its gene editing technology.
Part of preparing for commercialization will be a gene-edited cell manufacturing plant for commercial supplies of Cellectis’ off-the-shelf CAR-T therapies. Unlike the personalized autologous CAR-Ts already approved, which requires harvesting cells from each individual patient to tailor-make a treatment, Cellectis’ process can theoretically produce multiple batches from a single donor.
Following a deal that brand new Allogene struck with Pfizer, a team led by Arie Belldegrun and David Chang — the masterminds at Kite Pharma — has taken charge of developing UCART19. Meanwhile, the Cellectis team will continue to focus on Phase I studies of UCART123, which bounced back from a clinical halt just months ago.
CEO André Choulika, who’s had a respectful relationship with Belldegrun, told Endpoints News earlier that he expects the new partnership will accelerate the work on the lead therapy, with a shot at commercialization in late 2021 or 2022.
If all goes according to plan, Cellectis will be eligible to receive up to $2.8 billion in clinical and commercial milestone payments for 15 targets, according to the filing.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,600+ biopharma pros who read Endpoints News by email every day.Free Subscription